← boardnext 2027-01
ELVN
Enliven Therapeuticsdistress 1/10 · well-funded / low risk$51.98-2%today-4% from 52w high
Oncology 1
Lead: HER2 Amplification · target HER2
Revenue
pre-revenue
Liquidity
$452M
Runway
6.9 yrs
Shares 1y
+3%
Price & events
+92.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
+2.2%
1W
+6.9%
1M
+18.4%
3M
+101.6%
6M
+132.6%
1Y
+111.5%
2Y
+141.5%
5Y
-45.8%
All
Overview
- Market Cap
- $3.17B
- Volume
- 30.02K
- 52 Week Range
- $15.14 – $54.33
- Total Shares
- 60.90M
- Float Shares
- 53.27M
- Short %
- 17.39%
- % Held by Insiders
- 6.55%
- % Held by Institutions
- 90.17%
- RVOL
- 0.02x
- Beta
- 0.26
Pipeline stages · 1 programs
ELVN-001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-01 Estimated 50% readout ~2027-01-31 | Phase 1 | ELVN-002, Trastuzumab, 5-Fluorouracil | HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer | — | active not recruiting |
| 2027-12 Estimated 50% readout ~2027-12-31 | Phase 1 | ELVN-001 | Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml | — | recruiting |
| 2028-01 Estimated 50% readout ~2028-01-31 | Phase 1 | ELVN-001 | CML (Chronic Myelogenous Leukemia), Chronic Phase CML | — | recruiting |
| 2026-07 | Phase 1 | ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine | HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification | 198 | active not recruiting |
Catalyst news & presentations · 3
- 2026Guided 40%trial initiationsecondaryPhase 3ELVN-001 · Initiate first head-to-head Phase 3 pivotal trial.SEC 8-K
- 2026-08-12earningsEarningsEarnings releaseyahoo
- 2026-06-11fda agreementELVN-001 · FDA agreed on 80 mg QD as recommended dose for Phase 3 ENABLE-2 trial.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $66 (+27% upside) · 9 analysts
- 2026-07-21Goldman SachsBuy
- 2026-07-09HC Wainwright & Co.Buy
- 2026-07-01StifelBuy
- 2026-06-29Jones TradingBuy
- 2026-06-09StifelBuy
- 2026-06-02MizuhoOutperform
Competitors — HER2
Recent news
- 2026-07-22ELVN Maintained by Goldman Sachs -- Price Target Raised to $67.0 - GuruFocus
- 2026-07-22Enliven Therapeutics CFO Hohl sells $316,780 in stock - Investing.com India
- 2026-07-22Enliven Therapeutics chief medical officer Collins sells $263k in shares By Investing.com - Investing.com South Africa
- 2026-07-22Form 4 Enliven Therapeutics Inc For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-21Enliven Therapeutics Insider Sold Shares Worth $263,373, According to a Recent SEC Filing - marketscreener.com
- 2026-07-21Enliven Therapeutics Insider Sold Shares Worth $316,780, According to a Recent SEC Filing - marketscreener.com
- 2026-07-21Enliven Therapeutics (NASDAQ: ELVN) CFO sells 6,018 shares after option exercise - Stock Titan
- 2026-07-21Enterprise value to revenue forward of Enliven Therapeutics, Inc. – NASDAQ:ELVN - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.